- Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
- Innate Pharma to Participate in Upcoming Investor Conferences
- Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
- Outcome of Innate Pharma’s 2023 Annual General Meeting
- Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
- Number of shares and voting rights of Innate Pharma as of May 1, 2023
- Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
- Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
- Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
- Innate Pharma to Participate in Upcoming Investor Conference
Innate Pharma SA (IPH:PAR) closed at 2.78, 39.98% above the 52 week low of 1.99 set on Nov 10, 2022.
1.99Nov 10 20223.80Jan 16 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||223.65m EUR|
|EPS (TTM)||-0.7292 |
Data delayed at least 15 minutes, as of May 26 2023 16:36 BST.